Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Common Equity: 2021-2024

Historic Common Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $438.4 million.

  • Kiniksa Pharmaceuticals International's Common Equity rose 22.51% to $535.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $535.4 million, marking a year-over-year increase of 22.51%. This contributed to the annual value of $438.4 million for FY2024, which is 0.09% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Common Equity stood at $438.4 million for FY2024, which was down 0.09% from $438.8 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Common Equity's 5-year high stood at $438.8 million during FY2023, with a 5-year trough of $185.0 million in FY2021.
  • Its 3-year average for Common Equity is $424.5 million, with a median of $438.4 million in 2024.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Common Equity skyrocketed by 114.09% in 2022 and then dropped by 0.09% in 2024.
  • Kiniksa Pharmaceuticals International's Common Equity (Yearly) stood at $185.0 million in 2021, then soared by 114.09% to $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then declined by 0.09% to $438.4 million in 2024.